Craft
  • Home
  •  / Adaptimmune
Adaptimmune

Adaptimmune

Patents Issued

173

FY, 2016

Revenue

$6.1 M

FY, 2021

Market Capitalization

$207.8 M

2022-09-22

Adaptimmune Summary

Company summary

Overview
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.
Type
Public
Founded
2008
HQ
Philadelphia, PA, US | view all locations
Website
http://adaptimmune.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • David M. Mott

    David M. Mott, Chairman

    • Gavin Wood

      Gavin Wood, Chief Financial Officer

      • Lawrence M. Alleva

        Lawrence M. Alleva, Non-Executive Director

        • Helen Tayton-Martin

          Helen Tayton-Martin, Chief Business Officer

          Operating MetricsView all

          Patents Issued

          173

          FY, 2016

          Patent Applications

          69

          FY, 2016

          LocationsView all

          4 locations detected

          • Philadelphia, PA HQ

            United States

            351 Rouse Blvd

          • Milton, England

            United Kingdom

            101 Park Dr

          • Milton, England

            United Kingdom

            60 Jubilee Ave

          • Stevenage, England

            United Kingdom

            Gunnels Wood Rd

          Adaptimmune Financials

          Summary financials

          Revenue (Q2, 2022)
          $5.5M
          Net income (Q2, 2022)
          ($44.5M)
          Cash (Q2, 2022)
          $97.8M
          EBIT (Q2, 2022)
          ($43.8M)
          Enterprise value
          $134.1M

          Footer menu